BMO Capital Reiterates Biogen (BIIB) at Market Perform, Company's Investor Conference Does Not Invigorate Confidence

BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $238.00 price target on Biogen (NASDAQ: BIIB), following the company's investor conference.

The analyst quotes: "Biogen investor conference takeaways: Biogen CEO Michel Vounatsos presented at a conference today and highlighted the potential scenarios ahead of the NCD final decision (April 12) and lecanemab readout in September. Limited new information was shared, but we get the sense that the company is trying to draw attention to other parts of business (Immunology, Biosimilars, Digital Health) and away from AD/Neurology (elephant in the room), which does not invigorate confidence. Reiterate Mkt; $238 target."

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $209.45 yesterday.

By Vlad Schepkov | [email protected]

You May Also Be Interested In

• Wolfe Research Upgrades Biogen (BIIB) to Outperform
• Stifel Reiterates Buy Rating on Birkenstock Holding plc (BIRK)
• Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'